Dr. Bernd Seizinger, Md Phd
Chairman
Pharmaceuticals
Oxford BioTherapeutics
Switzerland
Biography
Dr. Bernd Seizinger has held a number of senior executive and board positions in both U.S. and European biotech and pharmaceutical companies including: President & CEO of GPC Biotech (Germany/U.S.); VP Oncology Drug Discovery & Molecular Genetics, and VP Corporate and Academic Alliances at Bristol-Myers-Squibb (U.S.); EVP/CSO of Genome Therapeutics (U.S.); CEO/Chairman of CryptoMedix (U.S.); Executive Chairman/Chairman of Aprea (Sweden/U.S.); and Executive/Chairman of Opsona (Ireland). Prior to his corporate appointments, Dr Seizinger held senior faculty positions at Harvard Medical School and Massachusetts General Hospital, and was a Visiting Professor at Princeton University during his tenure at Bristol-Myers Squibb. Dr. Seizinger also served on the board at Santhera Pharmaceuticals Holding AG. Dr. Seizinger received his doctorate degree from the Max-Planck-Institute for Molecular Genetics and a doctorate degree from Ludwig-Maximilians-Universität München.
Research Interest
Molecular Genetics
